(3R,4S)-3,4-dihydroxy-5-methylhexan-2-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3R,4S)-3,4-dihydroxy-5-methylhexan-2-one
• 化学式: C₇H₁₄O₃
• 分子量: 146.186
• InChiKey: DXNSLLFTQKUMDV-BQBZGAKWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (E)-5-甲基己-3-烯-2-酮 在 碳酸氢钠 、 potassium carbonate Hydroquinone 1,4-phthalazinediyl diether 、 potassium dioxotetrahydroxoosmate(VI) 、 potassium hexacyanoferrate(III) 作用下， 以 叔丁醇 为溶剂， 以87%的产率得到(3R,4S)-3,4-dihydroxy-5-methylhexan-2-one
  参考文献：
  名称：

  A Novel Strategy for the Convergent Synthesis of 1,3,5,…-Polyols: Enone Formation, Asymmetric Dihydroxylation, Reductive Cleavage, Hydride Addition

  摘要：

  α,β-不饱和酮的不对称二羟基化提供了高达 100% ee 的 α,β-二羟基酮。这些中间体或其双TMS 醚、丙酮化合物、苯硼酸盐或原甲酸盐的Cα-O 键被SmI2 裂解，得到β-羟基酮。后者可被还原以提供任何所需构型的顺式或反式1,3-二醇。

  DOI：

  10.1055/s-2005-921915

文献信息

• PYRIDINES AND PYRIMIDINES AND USE THEREOF
  申请人：Purdue Pharma L.P.

  公开号：US20170008882A1

  公开（公告）日：2017-01-12

  The present disclosure provides pyridines and pyrimidines of Formula I and pharmaceutically acceptable salts and solvates thereof: wherein A, G, W 1 , W 2 , W 3 , and R 5 are defined as set forth in the specification. The present disclosure also provides uses of the compounds of Formula I and pharmaceutically acceptable salts and solvates thereof. In certain embodiments, Compounds of the present disclosure are useful for treating pain. In another embodiment, Compounds of the present disclosure are useful for treating a disorder responsive to blockade of sodium channels, or alleviating symptoms of the disorder.

  本公开提供了Formula I的吡啶和嘧啶以及其药用可接受的盐和溶剂化合物：其中A、G、W1、W2、W3和R5如规范中所述。本公开还提供了Formula I化合物及其药用可接受的盐和溶剂的用途。在某些实施例中，本公开的化合物对治疗疼痛有用。在另一实施例中，本公开的化合物对治疗对钠通道阻滞有反应的疾病，或缓解该疾病的症状有用。
• Direct Asymmetric Aldol Reactions Inspired by Two Types of Natural Aldolases: Water-Compatible Organocatalysts and Zn^II Complexes
  作者：Joanna Paradowska、Monika Pasternak、Bartosz Gut、Beata Gryzło、Jacek Mlynarski

  DOI：10.1021/jo201584w

  日期：2012.1.6

  water-compatible amino-acid-based catalysts was explored in the development of diastereo- and enantioselective direct aldol reactions of a broad range of substrates. Chiral C2-symmetrical proline- and valine-based amides and their ZnII complexes were designed for use as efficient and flexible chiral catalysts for enantioselective aldol reactions in water, on water, and in the presence of water. The presence of

  在本文中，在开发多种底物的非对映和对映选择性直接羟醛反应中，探索了与水相容的氨基酸基催化剂的实用性。手性C 2对称的脯氨酸和缬氨酸基酰胺及其Zn II配合物被设计用作有效和灵活的手性催化剂，用于水，水和水存在下的对映选择性醛醇缩合反应。5 mol％的脯氨酰胺基催化剂的存在使未改性的酮与各种醛之间发生不对称的分子间羟醛反应，从而得到抗氧化剂。具有优异对映选择性的产品。我们还证明了对水具有较高亲和力的要求更高的底物（如丙酮和甲醛）的醛醇缩合反应。新设计的基于丝氨酸的有机催化剂促进了羟丙酮的醛醇缩合反应，生成了顺式二醇。对于提出的催化体系，无溶剂的条件也是可以接受的，这使得从绿色化学的角度出发，详细的方法变得很有趣。
• INDOLE DERIVATIVES AND USE THEREOF
  申请人：Purdue Pharma L.P.

  公开号：US20150284383A1

  公开（公告）日：2015-10-08

  The Invention provides indole derivatives of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R 1e , R 1f , A, X, Y, Z, and W 4 are defined as set forth in the specification. The Invention also provides the use of compounds of Formula I and the pharmaceutically acceptable salts and solvates thereof to treat pain. In certain embodiments, the Compounds of the Invention are effective in treating a disorder responsive to blockade of one or more sodium channels.

  本发明提供了公式I的吲哚衍生物及其药学上可接受的盐和溶剂化合物，其中R1e、R1f、A、X、Y、Z和W4如规范中所述。本发明还提供了利用公式I的化合物及其药学上可接受的盐和溶剂来治疗疼痛。在某些实施例中，本发明的化合物对于治疗对一个或多个钠通道阻滞有响应的疾病是有效的。
• DIBENZAZEPINE DERIVATIVES AND USE THEREOF
  申请人：Purdue Pharma L.P.

  公开号：US20150175569A1

  公开（公告）日：2015-06-25

  The present disclosure provides dibenzazepine derivatives having Formula I or I(A): and the pharmaceutically acceptable salts and solvates thereof, wherein R 3a , R 3b , R 6 , V 1 , V 2 , Z 1 , Z 2 , Z 3 , and G are defined as set forth in the specification. The present disclosure is also directed to the use of the compounds of Formula I or I(A), and the pharmaceutically acceptable salts or solvates thereof, to treat a disorder responsive to the blockade of one or more sodium channels. In one embodiment, the compounds of the present disclosure are useful for treating pain.

  本公开提供具有化学式I或I(A)的二苯并蒽啉衍生物及其药学上可接受的盐和溶剂化合物，其中R3a、R3b、R6、V1、V2、Z1、Z2、Z3和G的定义如规范中所述。本公开还涉及使用化合物I或I(A)及其药学上可接受的盐或溶剂化合物来治疗对阻断一个或多个钠通道敏感的疾病。在一个实施例中，本公开的化合物对治疗疼痛有用。
• Highly Efficient Organocatalyzed Direct Asymmetric Aldol Reactions of Hydroxyacetone and Aldehydes
  作者：Xiaoyu Wu、Zhixiong Ma、Zhengqing Ye、Shan Qian、Gang Zhao

  DOI：10.1002/adsc.200800558

  日期：2009.1

  Novel organocatalysts derived from L-threonine and L-leucine have been synthesized for catalyzing direct aldol reactions of hydroxycetone and unactivated aliphatic aldehydes with as low as 2 mol% loading of the catalyst, good to excellent yields and excellent enantioselectivities have been achieved for aliphatic aldehydes, whereas aromatic aldehydes yield only moderate enantioselectivities.

  合成了衍生自L-苏氨酸和L-亮氨酸的新型有机催化剂，用于催化羟基丙酮与未活化的脂族醛的直接醛醇缩合反应，催化剂的负载量低至2 mol％，对脂族醛具有良好至优异的收率和优异的对映选择性。 ，而芳族醛仅产生中等对映选择性。